By Finance Pulse in ACRS —

Aclaris Therapeutics Upgraded to Buy with $20 Target

Aclaris Therapeutics (ACRS) sees positive upgrade to Buy by H.C. Wainwright, following a lucrative exclusive license agreement. Price target set at $20.

A sleek and modern illustration featuring a financial chart ascending towards a $20 mark, symbolizin
Aclaris Therapeutics Upgraded to Buy with $20 Target

Upgraded to Buy by H.C. Wainwright due to a new exclusive license agreement.

Source